PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
A phase 2 trial of Flotufolastat F-18 in Prostate cancer, run by AdventHealth, now recruiting.
Overview
PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence is a phase 2 interventional study registered as NCT06617481 by AdventHealth, with 30 participants planned, started 2024-09-20 and due to reach its primary completion in 2027-09-05. Interventions recorded: 18F-rhPSMA-7.3 (Posluma). Conditions recorded: Prostate Cancer (Post Prostatectomy).
Linked to the drug Flotufolastat F-18 because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialDiagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
Shares Flotufolastat F-18, Prostate cancer and the tag pipeline.
- TrialAssessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Shares Flotufolastat F-18, Prostate cancer and the tag pipeline.
- TrialSafety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Shares Prostate cancer and the tag pipeline.
- TrialPhase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
Shares Prostate cancer and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialEvaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
Shares Prostate cancer and the tag pipeline.
- TrialStudy of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Shares Prostate cancer and the tag pipeline.
- TrialStudy of AZD0754 in Participants With Metastatic Prostate Cancer
Shares Prostate cancer and the tag pipeline.